Oral cancer primary prevention: Difference between revisions
Simrat Sarai (talk | contribs) No edit summary |
Simrat Sarai (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Oral cancer}} | |||
{{CMG}}{{AE}}{{Simrat}} | {{CMG}}{{AE}}{{Simrat}} | ||
==Overview== | ==Overview== | ||
Revision as of 20:19, 11 September 2015
|
Oral cancer Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Oral cancer primary prevention On the Web |
|
American Roentgen Ray Society Images of Oral cancer primary prevention |
|
Risk calculators and risk factors for Oral cancer primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Simrat Sarai, M.D. [2]
Overview
Effective measures for the primary prevention of oral cancer include tobacco cessation, alcohol cessation, eating variety of fruits and vegetables, and avoiding excessive sun exposure.
Primary Prevention
Tobacco cessation
Based on solid evidence, cessation of exposure to tobacco (e.g., cigarettes, pipes, cigars, and smokeless tobacco) leads to a decrease in the risk of cancer of the oral cavity and oropharynx.
Cessation of alcohol consumption
Based on fair evidence, cessation of alcohol consumption leads to a decrease in oral cavity cancer, but not until approximately 10 years after cessation. For cancer of the oropharynx, reduction in risk does not occur until approximately 20 years after cessation.
Human papillomavirus (HPV) Infection
Based on solid evidence, HPV 16 infection causes oropharyngeal cancer.HPV 16 is a sufficient but not necessary cause. Other high-risk HPV subtypes, including HPV 18, have been found in a small percentage of oropharyngeal cancers. Tobacco and alcohol use does not appear to be associated with increased risk among people with evidence of HPV 16 L1 seropositivity or oral HPV 16 infection. Vaccination against HPV 16 and the other high-risk subtypes has been found with inadequate evidence of a reduced risk of oropharyngeal Cancer. Vaccination against HPV 16 and 18 has been shown to prevent more than 90% of oral HPV 16/18 infections within 4 years of vaccination. Given the relatively recent onset of vaccination adoption and the age at which individuals are vaccinated, there is not yet evidence that vaccination at a young age will lead to a substantially reduced risk of HPV-associated oropharyngeal cancer later in life. In addition, no data are available to examine whether incidence or mortality would be reduced if vaccination occurred at an age closer to that at which oropharyngeal cancers tend to present.[1]